Blood tests to better diagnose early ovarian cancer types

The BIOC study is testing whether a panel of nine proteins found in blood can help doctors better distinguish between borderline ovarian tumors (which are often less serious) and stage I invasive ovarian cancer. Right now, existing blood tests like CA125 don't provide enough precision to tell these two types apart before surgery, which can lead to unnecessary procedures or the wrong treatment plan. This research aims to develop a more accurate blood test signature that could guide surgery decisions and help preserve fertility in younger patients when appropriate.

Current blood tests struggle to reliably separate borderline ovarian tumors from early invasive cancer before surgery, forcing doctors and patients to make treatment decisions without enough information. A better biomarker test could reduce unnecessary second surgeries, guide more personalized treatment, and help younger patients keep their fertility when safe to do so.